Short answer. REM sleep behaviour disorder (RBD) is a parasomnia in which the muscle paralysis that normally accompanies REM sleep fails, so the sleeper physically acts out dreams — talking, kicking, punching, sometimes leaping out of bed. In the general population it is rare; in Parkinson's disease it is common, often present years before motor symptoms, and is now considered one of the strongest prodromal markers of synucleinopathy (Postuma et al., 2015; Schenck et al., 2013). It is not a quirk. It is a documented injury risk for both the patient and the bed partner.
What's happening physiologically
In normal REM sleep, brainstem circuits actively paralyse skeletal muscle — atonia — so the body does not enact the dream. In RBD, the atonia mechanism fails, partially or completely. The dreamer's muscles do what the dream is asking them to do.
The literature is clear that RBD is not "vivid dreaming" or "restless sleep." It is a specific failure of REM atonia, diagnosable on polysomnography by the absence of muscle atonia during REM. The clinical picture includes punching, kicking, jumping out of bed, vocalisations, and dream content that is often violent or threat-related (being chased, fighting off an attacker).
Why this matters in Parkinson's specifically
The Postuma et al. (2015) longitudinal data — and the broader Schenck and Mahowald tradition — show that idiopathic RBD is a prodromal synucleinopathy: in long-term follow-up, more than 80% of people with idiopathic RBD eventually develop Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Once PD is established, RBD is present in roughly 30–50% of patients and is associated with:
Higher likelihood of cognitive impairment and PD dementia.
More disrupted sleep architecture overall.
Increased risk of injuries to both the person and the bed partner.
The Movement Disorder Society includes RBD in its prodromal PD criteria, and current AAN guidance treats it as both a clinical problem requiring management and a marker that warrants monitoring of cognition and autonomic function over time.
What the bed partner sees
Bed partners are often the only witnesses, since the dreamer is asleep. A typical pattern looks like:
Vocalisations during sleep — talking, shouting, swearing — often louder and more agitated than ordinary sleep talking.
Sudden movements: kicking, throwing arms, sitting up abruptly.
More dramatic episodes: leaping out of bed, falling, hitting the bed partner.
Episodes occurring in the second half of the night, when REM sleep is more prevalent.
The dreamer waking with no memory of having been physically active, or with vague memory of a vivid dream.
Bed-partner injuries are common. The Schenck literature documents bruises, lacerations, and occasional fractures from RBD episodes.
The conversation about safety — first, before treatment
Before any pharmacological discussion, the standard recommendations are environmental:
Move the bed against a wall, with the dreamer on the wall side, so leaping out is harder.
Pad the floor beside the bed if injury risk is high.
Move the bedside lamp, glasses, water, and any sharp objects out of arm's reach.
Move the bed partner to another bed in the same room or another room if episodes have caused injuries — this is not a relationship statement, it is a safety measure.
Lower the bed if possible; high beds increase the fall distance.
Window guards / locked windows if there is any history of leaving the bed.
Avoid REM-suppressing alcohol in the evening, which paradoxically can increase RBD severity on rebound.
The AASM (American Academy of Sleep Medicine) and the Movement Disorder Society both emphasise that environmental safety comes before pharmacology, and that for many milder cases environmental measures alone are sufficient.
Pharmacological options
When environmental measures are not enough or injuries have occurred, the medications with the strongest evidence are:
Melatonin (often 3–12 mg at bedtime). The first-line agent in many sleep medicine guidelines, with a favourable side-effect profile in older adults. Multiple trials show reduction in RBD episodes.
Clonazepam (typically 0.25–1 mg at bedtime). Long-established efficacy, but carries cognitive, balance, and falls risks in older adults — particularly in people with PD who are already prone to cognitive change. Many movement disorder specialists try melatonin first for this reason.
Other agents — pramipexole, rivastigmine, and rotigotine have been studied with mixed results.
The choice depends on age, cognitive status, fall risk, and whether the person is already on a complex PD regimen. This is a movement disorder specialist conversation.
Differential considerations
Not all sleep movement is RBD. Caregivers should be aware that:
Restless legs syndrome (RLS) is also common in PD but presents as an urge to move the legs at sleep onset, with relief on movement, not as enactment of dreams.
Periodic limb movements of sleep (PLMS) are stereotyped, repetitive limb movements during NREM sleep, not enacted dream content.
Nocturnal hallucinations in advanced PD or PD dementia can produce confusion, fear, and movement out of bed without the REM-specific signature.
Confusional arousals and sleepwalking are NREM parasomnias with different management.
A formal sleep study (polysomnography) is the gold standard for distinguishing RBD from these. The Movement Disorder Society and AASM both recommend polysomnography in suspected RBD, partly to confirm the diagnosis and partly to exclude obstructive sleep apnoea, which can produce RBD-like behaviour.
Time of night (more episodes in the second half is consistent with REM distribution).
Any associated dream content the person remembers.
Daytime consequences — daytime sleepiness, mood, cognitive fog the day after.
Any injuries to the dreamer or the bed partner.
This pattern data drives both medication decisions and monitoring of associated non-motor disease (cognition, autonomic function).
The cognitive dimension — why this matters beyond sleep
The Postuma and Schenck longitudinal data, and the more recent Iranzo et al. work, both establish that RBD severity is associated with faster cognitive decline in PD. The presence of RBD does not mean PD dementia is inevitable, but it warrants closer attention to:
Annual cognitive assessment (MoCA or similar).
Earlier conversations about advance care planning.
Closer monitoring for visual hallucinations and PD psychosis (often co-occurs with RBD).
Closer monitoring for autonomic symptoms (orthostatic hypotension, constipation, urinary symptoms).
This is not a reason for catastrophising; it is a reason for the clinical team to track non-motor markers more deliberately.
What the research suggests doing
Treat RBD as a real medical condition, not a sleep quirk.
Make the bedroom safe before discussing medication — wall-side bed, padded floor, removed bedside hazards.
Talk to the movement disorder specialist about melatonin first-line; clonazepam if needed.
Do not let bed-partner injuries continue while waiting for an appointment.
Track frequency and severity for the neurologist and the sleep specialist.
Use the presence of RBD as a trigger for more deliberate non-motor monitoring (cognition, autonomic function, hallucinations).
Postuma, R. B., et al. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591–1601.
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013). Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic RBD. Sleep Medicine, 14(8), 744–748.
Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284–2303.
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. V. (2006). Non-motor symptoms of Parkinson's disease. The Lancet Neurology, 5(3), 235–245.
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full Parkinson's caregiver research overview for the complete framework.